Discover the top 28 companies transforming the genomics market, including Thermo Fisher Scientific Inc., Illumina, Inc., Danaher Corporation, and other industry leaders. Backed by a market projected to grow from $47.07B to $85.09B by 2030 at a CAGR of 12.6%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.
Download PDF Brochure:“Click Here”
Spotlights on the Industry’s Top Genomics Companies
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a global powerhouse in the life sciences sector, providing an extensive array of analytical instruments, laboratory equipment, and diagnostic solutions. With a significant presence in the genomics market, the company offers industry-leading technologies through brands like Applied Biosystems and Invitrogen, supporting everything from high-throughput sequencing to everyday PCR applications. Their commitment to innovation and strategic acquisitions, such as PPD and Patheon, reinforces their position as a primary partner for researchers and clinicians aiming to advance personalized medicine and complex genetic analysis.
Illumina, Inc.
Illumina, Inc. is a preeminent leader in DNA sequencing and array-based technologies, fundamentally transforming the field of genomics since its inception. The company’s comprehensive portfolio, featuring the NovaSeq, NextSeq, and MiSeq platforms, enables researchers and clinicians to perform large-scale whole-genome sequencing and targeted genetic analysis with unprecedented speed and accuracy. Illumina’s focus on reducing the cost of sequencing while expanding its digital health and data analytics capabilities ensures its continued dominance in the clinical and research segments of the genomics market.
Danaher Corporation
Danaher Corporation operates as a global science and technology innovator, housing a prestigious family of life sciences brands including Cytiva, Beckman Coulter, and Integrated DNA Technologies (IDT). Through its Life Sciences and Diagnostics segments, Danaher provides essential tools for genomic medicine, from high-fidelity CRISPR components and synthetic biology tools to sophisticated laboratory automation and diagnostic systems. Their “Danaher Business System” drives operational excellence and continuous innovation, making them a critical infrastructure provider for the biopharmaceutical and clinical genomics industries.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. is a dominant force in the global diagnostics and pharmaceuticals market, with a specialized focus on personalized healthcare and molecular diagnostics. Through its Roche Diagnostics division, the company provides integrated genomic solutions, including the cobas series for high-throughput testing and advanced tissue diagnostics for oncology. Roche’s strategic integration of diagnostic insights with targeted therapies allows it to lead in the development of precision medicine, particularly in infectious diseases and cancer genomics.
Agilent Technologies, Inc.
Agilent Technologies, Inc. is a premier provider of core laboratory workflows and clinical diagnostic solutions, specializing in analytical instrumentation and software. In the genomics space, Agilent offers a robust portfolio of solutions for NGS library preparation, CRISPR genome editing, and array-based comparative genomic hybridization (aCGH). Their focus on providing high-quality reagents and automated systems helps researchers and pathologists achieve reliable, reproducible results in complex genetic research and routine clinical diagnostics.
Qiagen
Qiagen is a leading global provider of Sample to Insight solutions, specializing in technologies that allow for the isolation and processing of DNA, RNA, and proteins from diverse biological samples. The company’s portfolio includes advanced molecular diagnostic kits, bioinformatics software, and automated platforms designed for oncology testing, infectious disease screening, and human identification. Qiagen’s commitment to standardizing genomic workflows ensures that laboratories can transition seamlessly from raw sample preparation to actionable clinical insights.
Revvity
Revvity, formerly part of PerkinElmer, is a specialized life sciences company focused on providing innovative solutions for health science, ranging from discovery to cure. The company offers a wide range of genomic tools, including automated liquid handling, NGS library prep, and specialized imaging systems for high-content screening. Revvity’s emphasis on translational medicine and newborn screening positions it as a key player in the early detection of genetic disorders and the acceleration of drug discovery through advanced genomic analysis.
Laboratory Corporation Of America Holdings
Laboratory Corporation of America Holdings (Labcorp) is a leading global life sciences company that provides comprehensive laboratory services and drug development support. Labcorp operates one of the world’s largest clinical laboratory networks, offering extensive genomic and specialty testing services that facilitate early disease detection and personalized treatment planning. By integrating large-scale clinical data with innovative diagnostic tools, Labcorp plays a vital role in bringing genomic insights to primary care and specialized medical practices worldwide.
IQVIA Inc.
IQVIA Inc. is a global leader in advanced analytics, technology solutions, and clinical research services for the life sciences industry. The company leverages its massive data sets and “Connected Intelligence” to support the integration of genomics into clinical trials and real-world evidence studies. IQVIA’s capabilities in bioinformatics and patient-level data management help biopharmaceutical companies optimize the development of genomic therapies and improve market access for precision medicines.
Charles River Laboratories
Charles River Laboratories is a premier provider of essential products and services that support the pharmaceutical, biotechnology, and academic sectors throughout the drug discovery and development process. The company offers specialized genomic services, including gene therapy development, safety assessment, and custom animal models for genetic research. Charles River’s expertise in navigating the complex regulatory and manufacturing requirements for cell and gene therapies makes them an indispensable partner for organizations bringing novel genomic treatments to market.
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. In the genomics arena, Bio-Rad is highly regarded for its Droplet Digital PCR (ddPCR) technology, which provides absolute quantification of target DNA molecules with high sensitivity. Their portfolio also includes a variety of systems for electrophoresis, gene transfer, and real-time PCR, supporting diverse applications in disease research and clinical monitoring.
Eurofins Scientific
Eurofins Scientific is a global leader in bioanalytical testing, providing an unparalleled range of services across various industries, including clinical diagnostics and genomics. The company offers extensive DNA sequencing, genotyping, and gene synthesis services through its international network of specialized laboratories. Eurofins’ scale and technological breadth allow it to support large-scale population studies and provide rapid, high-quality genomic testing for personalized medicine, forensics, and agricultural biotechnology.
Pacbio
Pacbio (Pacific Biosciences of California, Inc.) is a pioneer in the development of long-read sequencing systems, offering high-fidelity (HiFi) sequencing technology that provides a more comprehensive view of complex genomes. Unlike traditional short-read methods, Pacbio’s platforms can accurately sequence long stretches of DNA, making them essential for identifying structural variations, de novo genome assembly, and resolving highly repetitive regions. Their commitment to improving the accuracy and throughput of long-read sequencing is expanding the possibilities for human genetics and plant and animal research.
Oxford Nanopore Technologies Plc.
Oxford Nanopore Technologies Plc. is a high-growth biotech company that has revolutionized genomic analysis with its portable, real-time nanopore sequencing technology. Their devices, ranging from the pocket-sized MinION to the high-throughput PromethION, allow for the direct sequencing of long DNA and RNA fragments without the need for complex lab infrastructure. This flexibility enables rapid genomic surveillance, field-based research, and clinical applications in diverse environments, challenging traditional centralized sequencing models.
Takara Bio Inc.
Takara Bio Inc. is a Japanese biotechnology company specializing in the development of innovative tools for life science research, gene therapy, and agricultural biotechnology. The company is a prominent provider of high-quality enzymes, kits for PCR and NGS library preparation, and specialized cell and gene therapy manufacturing services. Takara Bio’s focus on advancing regenerative medicine and providing essential reagents for molecular biology makes it a key contributor to the global genomics and biopharmaceutical industries.
BGI Group
BGI Group is one of the world’s largest genomics organizations, providing a comprehensive ecosystem of sequencing services, diagnostic tools, and research capabilities. Headquartered in China, the company operates across the entire genomics value chain, from manufacturing high-throughput sequencers through its subsidiary MGI to conducting large-scale population health studies. BGI’s massive data-processing capacity and commitment to making genomics accessible support global efforts in agriculture, infectious disease monitoring, and precision medicine.
Eppendorf SE
Eppendorf SE is a leading life science company that develops and sells instruments, consumables, and services for liquid handling, sample handling, and cell handling in laboratories worldwide. Their products, such as high-precision pipettes, centrifuges, and thermal cyclers, are foundational tools for genomic workflows, ensuring accuracy and reproducibility in DNA/RNA isolation and amplification. Eppendorf’s focus on ergonomic design and premium quality makes their equipment a standard in both academic research and industrial biotechnology labs.
Merck KGaA
Merck KGaA is a global science and technology company with a strong presence in healthcare, life science, and electronics. Through its Life Science business (MilliporeSigma in the U.S. and Canada), the company provides an extensive portfolio of reagents, consumables, and instruments for genomic research, including CRISPR-Cas9 gene editing tools and advanced cell culture systems. Merck’s commitment to fostering innovation in the biopharmaceutical industry through its integrated supply chain and technical expertise supports the rapid development of novel genomic therapies.
BD
BD (Becton, Dickinson and Company) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. In the genomics market, BD is recognized for its high-performance flow cytometry systems and single-cell multiomics platforms, such as the BD Rhapsody. These technologies enable researchers to analyze the genetic expression and protein profiles of individual cells, providing deep insights into immune system function and disease progression for oncology and immunology research.
Abbott
Abbott is a global healthcare leader with a diverse portfolio that includes market-leading solutions in diagnostics, medical devices, and nutrition. Within the genomics and molecular space, Abbott provides advanced platforms like the Alinity m for automated, high-volume infectious disease testing and oncology diagnostics. Their focus on delivering rapid, reliable, and scalable molecular results at the point of care and in centralized labs enhances clinical decision-making and patient management across the globe.
10x Genomics
10x Genomics is a high-growth life sciences technology company that specializes in single-cell and spatial biology solutions. Their platforms, including Chromium and Visium, allow researchers to examine the transcriptomes and genomes of individual cells within their tissue context, uncovering the complex cellular heterogeneity that traditional bulk sequencing methods miss. 10x Genomics’ innovative approach is driving breakthroughs in oncology, immunology, and neuroscience by providing a high-resolution map of biological systems.
New England Biolabs
New England Biolabs (NEB) is a recognized leader in the discovery and production of enzymes for molecular biology and genomic research. The company offers a vast selection of restriction enzymes, polymerases, and kits for NGS library preparation that are known for their high purity and performance. NEB’s dedication to scientific excellence and its role as a primary supplier of foundational tools make it an essential partner for researchers developing new molecular techniques and diagnostic assays.
Promega Corporation
Promega Corporation is a global leader in providing innovative solutions and technical support to the life sciences industry. The company offers an extensive range of products for genomics, including high-sensitivity assays for DNA/RNA quantification, bioluminescent reporters, and reagents for genetic identity testing. Promega’s focus on developing integrated systems for forensic analysis and clinical diagnostics helps laboratories achieve high-quality results in challenging applications such as human identification and molecular oncology.
Creative Biogene
Creative Biogene is a specialized biotechnology company providing a wide array of customized genomic services and products to support the global life sciences community. Their offerings include custom viral vector production, stable cell line development, and comprehensive NGS services. Creative Biogene’s flexibility and expertise in providing tailored solutions for gene editing and drug discovery make them a valuable resource for biopharmaceutical companies and academic institutions pursuing novel research targets.
Novogene Co., Ltd.
Novogene Co., Ltd. is a leading provider of genomic services and solutions, specializing in high-throughput sequencing and bioinformatics analysis. With a global network of advanced laboratories, Novogene offers a wide range of services including whole-genome sequencing, transcriptomics, and epigenomics for human, plant, and animal research. Their focus on delivering high-quality data and sophisticated computational analysis at scale enables researchers to accelerate their discoveries in personalized medicine and environmental science.
Helix, Inc.
Helix, Inc. is a population genomics company that combines a high-throughput clinical laboratory with an innovative data platform to support large-scale health studies and precision medicine initiatives. Helix partners with health systems and life sciences companies to provide “Sequence Once, Query Often” genomic data, allowing for long-term clinical insights and proactive population health management. Their focus on integrating genomic data into electronic health records is a significant step toward making genomics a routine part of clinical care.
Phalanx Biotech Group
Phalanx Biotech Group is a specialized genomic services provider that offers a comprehensive suite of microarray and NGS solutions for research and clinical applications. The company provides high-quality services for gene expression profiling, miRNA analysis, and genotyping, supported by robust bioinformatics tools. Phalanx Biotech’s commitment to providing reliable, cost-effective genomic analysis makes them a trusted partner for academic and industrial researchers focused on identifying genetic markers for disease and therapeutic response.
Polaris Genomics
Polaris Genomics is an emerging precision medicine company that specializes in using genomic insights to improve the diagnosis and treatment of neuropsychiatric conditions, such as PTSD. The company leverages its proprietary TruGenomix platform to identify objective genomic biomarkers for mental health disorders, aiming to move beyond subjective clinical assessments. Polaris Genomics’ focus on addressing the unmet needs in behavioral health through advanced molecular diagnostics highlights the expanding role of genomics in all areas of medicine.
Download PDF Brochure:“Click Here”
